R. A. Cercós-del-Pozo, F. Pérez-Giménez, Salabert-Salvador Mt, F. J. García-March, Miguel Murcia-Soler
{"title":"分子拓扑设计的新型降血药:2,6-二叔丁基-4-甲基吡啶和2,6-二叔丁基吡啶的药理学研究","authors":"R. A. Cercós-del-Pozo, F. Pérez-Giménez, Salabert-Salvador Mt, F. J. García-March, Miguel Murcia-Soler","doi":"10.1002/(SICI)1521-3838(199911)18:5<464::AID-QSAR464>3.0.CO;2-R","DOIUrl":null,"url":null,"abstract":"New compounds showing hypolipaemic activity have been designed using a computer-aided method based on molecular topology and QSAR analysis. Linear discriminant analysis and connectivity functions were used to design three potentially suitable drugs which were tested for hypolipaemic properties by the Triton WR-1339 test in rats. The pharmacological tests carried out on the newly designed compounds demonstrated the existence of notable activity in phase I for two of them. namely 2,6-Di-tert-butyl-4-methylpyridine (C.A.S. 38222-83-2) and 2,6-Di-tert-butylpyridine (C.A.S. 585-48-8), with respect to the level of total cholesterol. Both substances decrease the lipaemia to lower levels than clofibrate, which was used as a reference drug.","PeriodicalId":20818,"journal":{"name":"Quantitative Structure-activity Relationships","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1999-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"NEW HYPOLIPAEMIC AGENTS DESIGNED BY MOLECULAR TOPOLOGY : PHARMACOLOGICAL STUDIES OF 2,6-DI-TERT-BUTYL-4-METHYLPYRIDINE AND 2,6-DI-TERT-BUTYLPYRIDINE\",\"authors\":\"R. A. Cercós-del-Pozo, F. Pérez-Giménez, Salabert-Salvador Mt, F. J. García-March, Miguel Murcia-Soler\",\"doi\":\"10.1002/(SICI)1521-3838(199911)18:5<464::AID-QSAR464>3.0.CO;2-R\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"New compounds showing hypolipaemic activity have been designed using a computer-aided method based on molecular topology and QSAR analysis. Linear discriminant analysis and connectivity functions were used to design three potentially suitable drugs which were tested for hypolipaemic properties by the Triton WR-1339 test in rats. The pharmacological tests carried out on the newly designed compounds demonstrated the existence of notable activity in phase I for two of them. namely 2,6-Di-tert-butyl-4-methylpyridine (C.A.S. 38222-83-2) and 2,6-Di-tert-butylpyridine (C.A.S. 585-48-8), with respect to the level of total cholesterol. Both substances decrease the lipaemia to lower levels than clofibrate, which was used as a reference drug.\",\"PeriodicalId\":20818,\"journal\":{\"name\":\"Quantitative Structure-activity Relationships\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Quantitative Structure-activity Relationships\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/(SICI)1521-3838(199911)18:5<464::AID-QSAR464>3.0.CO;2-R\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Quantitative Structure-activity Relationships","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/(SICI)1521-3838(199911)18:5<464::AID-QSAR464>3.0.CO;2-R","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
NEW HYPOLIPAEMIC AGENTS DESIGNED BY MOLECULAR TOPOLOGY : PHARMACOLOGICAL STUDIES OF 2,6-DI-TERT-BUTYL-4-METHYLPYRIDINE AND 2,6-DI-TERT-BUTYLPYRIDINE
New compounds showing hypolipaemic activity have been designed using a computer-aided method based on molecular topology and QSAR analysis. Linear discriminant analysis and connectivity functions were used to design three potentially suitable drugs which were tested for hypolipaemic properties by the Triton WR-1339 test in rats. The pharmacological tests carried out on the newly designed compounds demonstrated the existence of notable activity in phase I for two of them. namely 2,6-Di-tert-butyl-4-methylpyridine (C.A.S. 38222-83-2) and 2,6-Di-tert-butylpyridine (C.A.S. 585-48-8), with respect to the level of total cholesterol. Both substances decrease the lipaemia to lower levels than clofibrate, which was used as a reference drug.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
